Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 12, 2009, Pages 1355-1360

  Milkiewicz, Piotr ^a,b   Buwaneswaran, Hayman ^a   Coltescu, Catalina ^a   Shums, Zakera ^c   Norman, Gary L ^c   Heathcote, E Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; GP210 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; M2 ANTIBODY; MITOCHONDRION ANTIBODY; SP100 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT DISEASE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRAHEPATIC CHOLESTASIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS;

AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS;

EID: 70849091483     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.07.012     Document Type: Article

References (23)

1. Czaja A.J., and Norman G.L. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 37 (2003) 315-329
2. Worman H.J., and Courvalin J.C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2 (2003) 211-217
3. Kita H., Nalbandian G., Keeffe E.B., et al. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 7 (2003) 821-839
4. Gabeta S., Norman G.L., Liaskos C., et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 27 (2007) 378-387
5. Miyakawa H., Tanaka A., Kikuchi K., et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 34 (2001) 243-248
6. Muratori P., Muratori L., Gershwin M.E., et al. "True" antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol 135 (2004) 154-158
7. Szostecki C., Will H., Netter H.J., et al. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol 36 (1992) 555-564
8. Bandin O., Courvalin J.C., Poupon R., et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 23 (1996) 1020-1024
9. Tartakovsky F., and Worman H.J. Detection of Gp210 autoantibodies in primary biliary cirrhosis using a recombinant protein containing the predominant autoepitope. Hepatology 21 (1995) 495-500
10. Nickowitz R.E., and Worman H.J. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 178 (1993) 2237-2242
11. Nakamura M., Shimizu-Yoshida Y., Takii Y., et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 42 (2005) 386-392
12. Leung P.S., Rossaro L., Davis P.A., et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46 (2007) 1436-1442
13. Manns M., Gerken G., Kyriatsoulis A., et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1 (1987) 292-294
14. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355 (2000) 1510-1515
15. Oertelt S., Rieger R., Selmi C., et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 45 (2007) 659-665
16. Muratori P., Muratori L., Ferrari R., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 431-437
17. O'Brien C., Joshi S., Feld J.J., et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 48 (2008) 550-556
18. Mitchison H.C., Bassendine M.F., Malcolm A.J., et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 10 (1989) 420-429
19. Rautiainen H., Karkkainen P., Karvonen A.L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41 (2005) 747-752
20. Yang W.H., Yu J.H., Nakajima A., et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2 (2004) 1116-1122
21. Rigamonti C., Shand L.M., Feudjo M., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 55 (2006) 388-394
22. Nakamura M., Komori A., Ito M., et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res 37 Suppl 3 (2007) S412-S419
23. Czaja A.J., Shums Z., Binder W.L., et al. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 48 (2003) 1658-1664